Koers Hemostemix Inc Toronto S.E.
Aandelen
CA4236941080
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 6,1 mln. 8,38 mln. 5,7 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -5 mln. -6,87 mln. -4,67 mln. | Nettowinst (verlies) 2023 | -2 mln. -2,75 mln. -1,87 mln. | EV/omzet 2022 | - |
Nettoschuld 2022 | 3,99 mln. 5,48 mln. 3,73 mln. | Nettoschuld 2023 | 4,17 mln. 5,73 mln. 3,89 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-2,41
x | K/w-verhouding 2023 |
-2,31
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 87,8% |
Recentste transcriptie over Hemostemix Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Smeenk
FOU | Founder | - | 01-01-06 |
Christina Wu
DFI | Director of Finance/CFO | - | 05-03-20 |
Peter Pavlin
COO | Chief Operating Officer | - | 19-05-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Peter Lacey
CHM | Chairman | 67 | 11-03-20 |
Ronnie Hershmann
BRD | Director/Board Member | - | 09-02-20 |
Thomas Smeenk
FOU | Founder | - | 01-01-06 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,15% | 124 mld. | |
+18,02% | 112 mld. | |
+5,07% | 22,94 mld. | |
-12,75% | 22,22 mld. | |
-9,86% | 17,02 mld. | |
-14,97% | 16,88 mld. | |
-39,94% | 16,87 mld. | |
+2,80% | 13,63 mld. | |
+27,39% | 11,61 mld. |